相关实验视频
Updated: Jun 29, 2025

04:50
An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
377
治疗肥胖的药物的有效性和安全性
Kristina Henderson, Lewis1,2, Caroline E Sloan2,3,4
1Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, NC, USA khlewis@wakehealth.edu.
概括
新的抗肥胖药物 (AOMs) 为肥胖治疗提供了更好的疗效和安全性. 然而,提供者犹和缺乏保险覆盖等进入障碍仍然存在,需要个性化患者护理策略.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 公共卫生 公共卫生
背景情况:
- 最近对抗肥胖药物 (AOM) 的关注凸显了药物治疗在肥胖管理中的作用.
- 新的AOM显示出比较旧的治疗方法更高的疗效和安全性.
- 进入AOM的障碍包括提供者不适,耻辱和保险覆盖不足.
研究的目的:
- 强调医疗保健提供者必须讨论AOM风险和益处的全方位.
- 倡导在AOM处方中将基于指南的建议与现实世界的临床证据相结合.
- 解决患者对AOM反应的变异性,促进灵活,个性化的治疗方法.
主要方法:
- 关于抗肥胖药物的当前文献的综述.
- 分析影响处方模式和患者获取的因素.
- 讨论临床证据和患者反应的变化.
主要成果:
- 新的AOM在有效性和安全性方面具有显著的优势.
- 提供者偏见,肥胖污名和保险限制限制了获得有效的AOM的机会.
- 由于患者对AOM的反应变化,个性化治疗方法至关重要.
结论:
- 医疗保健提供者必须具备导航AOM选项,风险和个性化肥胖药物治疗的好处的设备.
- 需要进一步研究现实世界的AOM利用,组合疗法和成本效益.
- 肥胖药物治疗的未来似乎充满希望,随着新药治疗的不断发展.
更多相关视频
相关概念视频
Dose-Response Relationship: Potency and Efficacy
4.4K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.4K
Oral Hypoglycemic Agents: Biguanides and Glitazones
196
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
196
Antidepressant Drugs: MAOIs and Other Agents
228
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
228
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Principles of Drug Action
6.0K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
6.0K

